CLH Stock Chart & Stats
€202.40
€2.10(1.05%)
At close: 4:00 PM EDT
€202.40
€2.10(1.05%)
Day’s Range― - ―
52-Week Range€124.60 - €210.30
Previous CloseN/A
Volume0.00
Average Volume (3M)8.00
Market Cap
€46.70B
Enterprise Value€55.01K
Total Cash (Recent Filing)€3.94B
Total Debt (Recent Filing)€8.92B
Price to Earnings (P/E)35.1
Beta0.17
Next Earnings
Aug 11, 2026EPS Estimate
2.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.56
Shares Outstanding234,205,860
10 Day Avg. Volume7
30 Day Avg. Volume8
Financial Highlights & Ratios
PEG Ratio0.30
Price to Book (P/B)-14.56
Price to Sales (P/S)0.18
P/FCF Ratio21.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€220.55Price Target Upside8.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)10.61
Revenue Forecast (FY)€242.09B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GenerationConsistently strong operating cash flow (~$5.0B TTM) and robust free cash flow (~$4.4B TTM) provide durable internal funding for debt reduction, share repurchases, and strategic investments. This cash conversion supports multi‑quarter capital allocation and resilience to working‑capital swings.
Raised Guidance And ExecutionManagement raised and narrowed FY2026 EPS and increased adjusted FCF guidance, reflecting sustained operational improvement. Elevated guidance implies greater visibility into earnings and cash generation over the coming quarters, signalling stronger underlying business performance and credible execution.
Scale And Diversified Growth BusinessesLarge pharma distribution scale (Q3 pharma revenue ~$56.1B) plus high‑growth Specialty and Other businesses (double‑digit/30%+ growth in growth segments) diversify revenue and reduce cyclicality. Scale drives purchasing leverage and helps absorb margin pressure while higher‑growth units raise long‑term earnings potential.
Bears Say
Weak Balance Sheet / Negative EquityPersistently negative equity and nearly $9B of debt materially weaken the capital cushion and magnify leverage metrics. This structural shortfall reduces financial flexibility, increases refinancing and interest‑rate vulnerability, and constrains the firm's ability to absorb shocks or pursue large strategic moves over months.
Structurally Thin MarginsAs a high‑volume, low‑margin distributor (TTM gross ~3.7%, net ~0.6%), profitability is highly sensitive to pricing, mix shifts, and cost increases. Small adverse moves—reimbursement changes, tariff pass‑through limits, or WAC/IRA effects—can materially compress earnings absent sustained scale or persistent efficiency gains.
Regulatory, Tariff And Impairment RisksSignificant tariff payments (~$200M) with uncertain refunds and a $184M goodwill impairment highlight recurring regulatory and integration risks. Policy changes and tariff outcomes can create quarterly earnings volatility and contingent liabilities, reducing long‑term cash visibility and increasing execution risk.
Cardinal Health News
CLH FAQ
What was Cardinal Health’s price range in the past 12 months?
Cardinal Health lowest stock price was €124.60 and its highest was €210.30 in the past 12 months.
What is Cardinal Health’s market cap?
Cardinal Health’s market cap is €46.70B.
When is Cardinal Health’s upcoming earnings report date?
Cardinal Health’s upcoming earnings report date is Aug 11, 2026 which is in 9 days.
How were Cardinal Health’s earnings last quarter?
Cardinal Health released its earnings results on Apr 30, 2026. The company reported €2.748 earnings per share for the quarter, beating the consensus estimate of €2.423 by €0.325.
Is Cardinal Health overvalued?
According to Wall Street analysts Cardinal Health’s price is currently Undervalued.
Does Cardinal Health pay dividends?
Cardinal Health does not currently pay dividends.
What is Cardinal Health’s EPS estimate?
Cardinal Health’s EPS estimate is 2.1.
How many shares outstanding does Cardinal Health have?
Cardinal Health has 234,205,860 shares outstanding.
What happened to Cardinal Health’s price movement after its last earnings report?
Cardinal Health reported an EPS of €2.748 in its last earnings report, beating expectations of €2.423. Following the earnings report the stock price went down -1.057%.
Which hedge fund is a major shareholder of Cardinal Health?
Currently, no hedge funds are holding shares in DE:CLH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cardinal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€220.55 (8.97% Upside)
€220.55 (8.97% Upside)
Blogger Sentiment
Bullish
DE:CLH Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.56%
12-Months-Change
Fundamentals
Return on Equity
0.90%
Trailing 12-Months
Asset Growth
13.67%
Trailing 12-Months
Company Description
Cardinal Health
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
CLH Company Deck
CLH Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted broad-based operational strength: solid top-line growth, outsized EPS improvement, robust free cash flow generation, meaningful outperformance in Specialty and other growth businesses, and a raised, narrowed FY26 outlook. Challenges noted include a $184M goodwill impairment for Navista, tariff-related pressure in the GMPD business with uncertain refunds (paid ~ $200M to date), higher headline SG&A and rising interest costs, and revenue mix headwinds from IRA/WAC adjustments and GLP-1 moderation. On balance the company emphasized durable fundamentals, disciplined capital deployment (including $1B of buybacks), successful integration of acquisitions and confidence in long-term targets.View all DE:CLH earnings summariesCLH Revenue Breakdown
91.94% Pharmaceutical and Specialty Solutions
5.68% Global Medical Products and Distribution
2.42% Other
-0.04% Corporate

CLH Stock 12 Month Forecast
All Analysts
Top Analysts
Average Price Target
€220.55
▲(8.97% Upside)
Technical Analysis
1 Day
3 Days
1 Week
1 Month











